Browse Drug Recalls
1,317 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,317 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,317 FDA drug recalls in IL.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Oct 29, 2018 | Clindamycin Phosphate Topical Solution USP, 1% (10 mg/mL clindamycin), 60 ple... | Failed Impurities/Degradation Specifications; out of specification results observed for other ind... | Class III | Akorn, Inc. |
| Oct 15, 2018 | Metoprolol Tartrate Injection, USP, 5 mg/ 5 mL (1 mg/mL), 5 mL per sterile si... | Failed pH Specifications: Upward shift in the pH of the solution within the shelf life of the imp... | Class III | Baxter Healthcare Corporation |
| Oct 8, 2018 | Gentamicin Sulfate Ophthalmic Solution, USP 0.3%, 5 mL dropper bottle, Rx Onl... | Presence of Particulate Matter: Crystalline particles were noticed at the 24 month clarity testing. | Class II | Akorn, Inc. |
| Oct 8, 2018 | 5% Dextrose Injection, USP, Rx Only, a) 25 mL NDC 0409-7923-20; b) 250 mL NDC... | Lack of Assurance of Sterility; bags have the potential to leak | Class II | ICU Medical Inc |
| Oct 8, 2018 | 0.9% Sodium Chloride Injection, USP Rx Only a) 250 mL NDC 0409-7983-02; b) 15... | Lack of Assurance of Sterility; bags have the potential to leak | Class II | ICU Medical Inc |
| Sep 25, 2018 | Levofloxacin Injection in 5% Dextrose, 5 mg/mL, packaged in a) 50 mL (NDC 360... | Superpotent Drug: High out of specification results for levofloxacin resulting in increased conce... | Class III | Baxter Healthcare Corporation |
| Sep 17, 2018 | SparkleFresh Fluoride Toothpaste, Sodium Monofluorophosphate 0.76%, a) 17 g t... | Microbial Contamination of Non-Sterile Product | Class II | Medline Industries Inc |
| Sep 10, 2018 | Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 1... | Defective Delivery System: tablets may be missing, in whole or in part, the laser drilled holes o... | Class II | Takeda Development Center Americas, Inc. |
| Sep 6, 2018 | 0.9% Sodium Chloride Injection USP 50 mL Viaflex container Baxter Healthcare ... | cGMP Deviation | Class II | Baxter Healthcare Corporation |
| Aug 24, 2018 | Ethosuximide Capsules, USP, 250 mg, 100 capsules per bottle, Rx only, Mfg For... | Failed Impurities/Degradation Specifications: Out of specification (OOS) results for unspecified ... | Class II | Akorn, Inc. |
| Aug 21, 2018 | 0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Co... | CGMP Deviations | Class II | Baxter Healthcare Corporation |
| Aug 14, 2018 | Diltiazem HCl Extended-release Capsules, USP 120 mg, 80 capsules, 8 blister c... | Failed Impurities/Degradation Specifications; out of specification results for related compound p... | Class III | Mylan Institutional, Inc. (d.b.a. UDL Laborator... |
| Aug 8, 2018 | Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle... | Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-... | Class III | Akorn, Inc. |
| Aug 1, 2018 | Levofloxacin Injection in 5% Dextrose, 500 mg (5 mg/mL), 500 mg in 100 mL 5% ... | Superpotent Drug: High out of specification results for levofloxacin resulting in increased conce... | Class III | Baxter Healthcare Corporation |
| Aug 1, 2018 | Levofloxacin Injection in 5% Dextrose, 750 mg (5 mg/mL), 750 mg in 150 mL 5% ... | Superpotent Drug: High out of specification results for levofloxacin resulting in increased conce... | Class III | Baxter Healthcare Corporation |
| Aug 1, 2018 | Lidocaine 2.5% and Prilocaine Cream, 2.5%. 30g tube, Rx only, Manufactured by... | Failed Impurities/Degredation Specifications: Out of Specification results for an unknown impuri... | Class II | Akorn, Inc. |
| Aug 1, 2018 | Levofloxacin Injection in 5% Dextrose, 250 mg (5 mg/mL), 250 mg in 50 mL 5% D... | Superpotent Drug: High out of specification results for levofloxacin resulting in increased conce... | Class III | Baxter Healthcare Corporation |
| Jul 24, 2018 | Prednisolone Sodium Phosphate Oral Solution, 15 mg/5 mL, 8 fl oz (237 mL) Bot... | Defective Container: Tamper Evident foil seal not completely intact. | Class II | Morton Grove Pharmaceuticals, Inc. |
| Jul 17, 2018 | Valsartan Tablets, 160 MG, 30-count bottle (NDC 54569-6583-0), 90-count bottl... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 17, 2018 | Valsartan and Hydrochlorothiazide Tablets, Valsartan 160 MG and Hydrochloroth... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 17, 2018 | Valsartan Tablets, 80 MG, 30-count bottle (NDC 54569-6582-0, 90-count bottle ... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 17, 2018 | Valsartan and Hydrochlorothiazide Tablets, Valsartan 320 MG and Hydrochloroth... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 3, 2018 | Monsel's Solution (Ferric Subsulfate), 20%, packaged as 12 single application... | CGMP Deviations: The manufacturer of this product recalled because they were not manufactured und... | Class II | Medgyn Products, Inc. |
| Jun 28, 2018 | Daptomycin for Injection, 500 mg per vial, packaged as 1 Single-dose vial per... | Microbial Contamination of Sterile Products: Product associated with reports of adverse events in... | Class II | PFIZER |
| Jun 22, 2018 | Acetylcysteine for Injection 6 g/30 mL (200 mg/mL). Rx Only. Manufactured by ... | CGMP Deviations | Class II | Akorn, Inc. |
| Jun 4, 2018 | Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Si... | Presence of Particulate Matter; Potential for particulate matter on the syringe plunger. | Class I | HOSPIRA INC, LAKE FOREST |
| May 31, 2018 | 0.45% Sodium Chloride Injection, USP, 100 mL bag, Rx Only, Hospira, Inc. Lake... | Lack of assurance of sterility: Bags have potential to leak. | Class II | ICU Medical Inc |
| May 31, 2018 | 0.9% Sodium Chloride Injection, USP, 100 mL bag, Rx Only, Hospira, Inc. Lake ... | Lack of assurance of sterility: Bags have potential to leak. | Class II | ICU Medical Inc |
| May 31, 2018 | 0.9% Sodium Chloride Injection, USP, 100 mL bag, Rx Only ,Hospira, Inc. Lake ... | Lack of assurance of sterility: Bags have potential to leak. | Class II | ICU Medical Inc |
| May 31, 2018 | 5% Dextrose Injection, USP, 250 mL bag, Rx Only, Hospira, Inc. Lake Forest, I... | Lack of assurance of sterility: Bags have potential to leak. | Class II | ICU Medical Inc |
| May 31, 2018 | 0.9% Sodium Chloride Injection, USP, 250 mL bag, Rx Only, Hospira, Inc. Lake ... | Lack of assurance of sterility: Bags have potential to leak. | Class II | ICU Medical Inc |
| May 22, 2018 | READYFLUSH PROTECT with Dimethicone (3.2%), Flushable Personal Cleaning Cloth... | Microbial Contamination of a Non-Sterile Product. | Class II | Medline Industries Inc (Northpoint Services) |
| May 1, 2018 | Loxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Ma... | GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violatio... | Class II | Mylan Institutional, Inc. (d.b.a. UDL Laborator... |
| May 1, 2018 | Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Ma... | GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violatio... | Class II | Mylan Institutional, Inc. (d.b.a. UDL Laborator... |
| Apr 10, 2018 | Vasopressin 50 Units added to 250 mL 0.9% Sodium Chloride Injection USP (0.2 ... | cGMP deviations | Class III | Pharmedium Services, LLC |
| Mar 29, 2018 | Chlorhexidine Gluconate Oral Rinse, 0.12%, 15 mL unit dose cups (NDC 50383-72... | Subpotent Drug: Product crystallization with accompanying low out of specification results for ch... | Class III | Akorn, Inc. |
| Mar 29, 2018 | 24-HOUR Oral Care q4 Kit with Ballard* Technology, containing 2 Toothbrush Pa... | Subpotent Drug: Product crystallization with accompanying low out of specification results for ch... | Class III | Akorn, Inc. |
| Mar 29, 2018 | 24-HOUR Oral Care q2 Kit with Ballard* Technology, containing 2 Toothbrush Pa... | Subpotent Drug: Product crystallization with accompanying low out of specification results for ch... | Class III | Akorn, Inc. |
| Mar 9, 2018 | Triamcinolone Acetonide Lotion, USP 0.1%, 60 mL bottle, Rx Only, Marketed by:... | Failed Impurities/Degradation Specifications: High out of specification results for an impurity. | Class III | Akorn, Inc. |
| Mar 9, 2018 | Psoriasin Daytime Relief Cream with Vitamin D & Oatmeal, (Coal Tar 1.25%), pa... | Subpotent Drug: The product has failed to maintain its label claim of coal tar throughout its lab... | Class III | Alva-Amco Pharmacal Companies., Inc. |
| Mar 5, 2018 | methylPREDNISolone Sodium Succinate for Injection, USP, 125 mg* per vial, Sin... | Failed Impurities/Degradation Specifications: High out of specification results for an impurity. | Class II | Sagent Pharmaceuticals Inc |
| Mar 5, 2018 | methylPREDNISolone Sodium Succinate for Injection, USP, 1 gram* per vial, Sin... | Failed Impurities/Degradation Specifications: High out of specification results for an impurity. | Class II | Sagent Pharmaceuticals Inc |
| Mar 5, 2018 | methylPREDNISolone Sodium Succinate for Injection, USP, 40 mg* per vial, Sing... | Failed Impurities/Degradation Specifications: High out of specification results for an impurity. | Class II | Sagent Pharmaceuticals Inc |
| Feb 21, 2018 | Atropine Sulfate Ophthalmic 1% Solution, USP, 5mL per bottle, Sterile, Rx Onl... | Failed Stability Specification: OOS low viscosity results discovered during retain testing. | Class III | Akorn, Inc. |
| Feb 15, 2018 | PVP Scrub Solution, Povidone Iodine, 7.5% (equivalent to 0.75% available iodi... | Subpotent Drug: product not meeting the iodine assay level requirements through the labeled expiry. | Class II | Medline Industries Inc |
| Jan 22, 2018 | Mycamine (micafungin) for Injection 100 mg/vial Single-Dose Vial Rx only Mar... | Labeling: Label Error on Declared Strength | Class II | Astellas Pharma US Inc |
| Jan 22, 2018 | Ultane (sevoflurane), 250 mL, Inhalation Anesthetic, Rx only, Manufactured by... | Defective container: presence of a hole in the liners of the caps covering the product bottle, in... | Class III | AbbVie Inc. |
| Jan 16, 2018 | Vecuronium bromide for Injection, 10 mg vials, Rx only, Mfd. for: Fresenius K... | Failed impurities/ degradation specifications: Out-of-specification (OOS) result for USP related ... | Class III | Fresenius Kabi USA, LLC |
| Dec 27, 2017 | Ropivacaine HCl Injection in all strengths, all doses, and all packaging. | Lack of sterility assurance. | Class II | Pharmedium Services, LLC |
| Dec 27, 2017 | Dexamethasone Sodium Phosphate in all strengths, all doses, and all packaging. | Lack of sterility assurance. | Class II | Pharmedium Services, LLC |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.